Maintenance CC-486 Improves OS in Newly Diagnosed AML
Maintenance therapy with CC-486 (oral azacitidine) led to a highly statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with newly diagnosed acute myeloid leukemia who achieved first complete response or CR with incomplete blood count recovery with induction therapy.
Source: OncLive